Demonstrate Efficacy and Safety of Metastatic Breast Cancer

A Double-blind, Randomised, Parallel Group, Phase III Study to Demonstrate Equivalent Efficacy and Comparable Safety of CT-P6 and Herceptin, Both in Combination With Paclitaxel, in Patients With Metastatic Breast Cancer

The purpose of the study is to demonstrate equivalence

Patients will receive CT-P6 or Herceptin every 3 weeks.

Inclusion Criteria:

• Are females
• Have Her 2 over-expression
• Have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

Exclusion Criteria:

• Current clinical or radiographic evidence central nervous system (CNS) metastases
• Current Known infection
• Pregnant or nursing mother